*Streptococcus pneumoniae* (pneumococcus) has long been recognized as a major cause of serious infections, especially pneumonia and meningitis. In 1983, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) was licensed in the United States and subsequently recommended by the Advisory Committee on Immunization Practices (ACIP) for all persons aged ≥65 years as well as those aged ≥2 years with chronic illnesses associated with an increased risk of pneumococcal infection or complications thereof \[[@OFU024C1]\]. In subsequent recommendations, the ACIP divided persons with such chronic illnesses into 2 groups: immunocompetent persons and immunocompromised persons \[[@OFU024C2]\]. In 2010, asthma and cigarette smoking were added to the list of vaccine-eligible conditions among immunocompetent adults \[[@OFU024C3]\]. In 2011, the 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in the United States, and the ACIP recommended in 2012 that adults aged ≥19 years with immunocompromising conditions, anatomic or functional asplenia, cerebrospinal fluid leaks, or cochlear implants receive PCV13 followed by PPSV23 \[[@OFU024C4]\].

Although it is widely accepted that adults with immunocompromising medical conditions are at greatly increased risk for pneumococcal infection, the magnitude of risk among immunocompetent adults with some of the chronic illnesses identified by the ACIP is less certain, because current estimates are based primarily on small case series or community surveys. Moreover, in the current era of universal vaccination of children with pneumococcal conjugate vaccines---with consequent disease reduction in the adult population via herd (indirect) effects---it is unclear whether the increased risks for pneumococcal infections associated with certain chronic medical conditions have persisted \[[@OFU024C5], [@OFU024C6]\].

Therefore, we analyzed recent data from 3 large healthcare claims repositories in the United States to examine rates of all-cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease (IPD) among adults with and without 1 or more of the chronic illnesses currently listed in the ACIP guidelines as indications for pneumococcal vaccination. In addition, we examined disease rates among adults with several other conditions that might increase infection risk based on limited data from other studies, including 3 autoimmune diseases---rheumatoid arthritis, systemic lupus erythematosus (SLE), and Crohn\'s disease---and neuromuscular (chiefly cerebral palsy) and seizure disorders \[[@OFU024C7]--[@OFU024C9]\]. Finally, we examined the impact of risk stacking among the at-risk population, by estimating disease rates within subgroups defined on the basis of the number of concurrent conditions.

METHODS {#s2}
=======

Study Design {#s2a}
------------

A retrospective cohort design was used. Study cohorts were identified at the beginning of each calendar year of observation---from 2007 to 2010---and study subjects were characterized in terms of the presence of underlying medical conditions (ie, risk profile) based on information recorded at any time before January 1st of that calendar year. For each cohort, episodes of disease (ie, all-cause pneumonia, pneumococcal pneumonia, and IPD) were ascertained during the 1-year period beginning on January 1st of each corresponding year and ending on December 31st of that year (or the date of loss to follow-up, if earlier). Subjects who met criteria for inclusion in multiple calendar years contributed data to each cohort for which they were eligible.

Data Source {#s2b}
-----------

Data spanning January 1, 2006 through December 31, 2010 from 3 large integrated healthcare claims repositories were pooled for analyses. The 3 repositories---(1) Truven Health Analytics MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases; (2) IMS LifeLink PharMetrics Health Plan Claims Database; and (3) Optum Research Database---include medical (ie, facility and professional-service) claims and outpatient pharmacy claims from private US health plans. Together, these 3 geographically diverse repositories capture healthcare claims information for \>35 million plan members annually.

Data available from each facility and professional-service claim included dates and places of service, diagnoses (ICD-9-CM), procedures performed and services rendered (ICD-9-CM, HCPCS), and quantity of services (professional-service claims). Data available for each outpatient pharmacy claim included the drug dispensed, dispensing date, quantity dispensed, and number of days supplied. Selected demographic and eligibility information (including age and year of birth, sex, geographic region of residence, dates of plan eligibility) also were available.

Patient-identifying information was encrypted or removed from the study databases before their release to study investigators. Use of these study databases for health-services research is therefore fully compliant with the HIPAA Privacy Rule and federal guidance on Public Welfare and the Protection of Human Subjects (Public Welfare---Protection of Human Subjects; 45CFR 46 §46.101).

Study Population {#s2c}
----------------

The study population comprised adults aged ≥18 years who were enrolled in participating health plans on the first day of 1 or more calendar year(s) from 2007 to 2010. Study subjects were stratified based on their age (18--49, 50--64, and ≥65 years) and risk profile ("at-risk", "high-risk", and "healthy") as of the beginning of each year.

Risk profiles were defined by the presence of medical conditions for which the ACIP currently recommends pneumococcal vaccination in adults \[[@OFU024C4]\], or other medical conditions that we hypothesized may increase the risk of pneumococcal disease despite not currently being recognized by the ACIP. Immunocompetent persons with ≥1 chronic medical condition identified by the ACIP, or with neuromuscular or seizure disorders, autoimmune diseases (rheumatoid arthritis, SLE, and Crohn\'s disease), or chronic use of steroids (defined as receipt of ≥30 days of oral corticosteroid therapy during the past year) were classified as at-risk. Immunocompromised or immunosuppressed persons and those with a cochlear implant were classified as high-risk. At-risk and high-risk were mutually exclusive categories, and thus, for example, persons considered immunosuppressed due to cancer treatment were included in the high-risk category only, even if they also had an at-risk condition. Persons without evidence of at-risk or high-risk conditions were classified as healthy.

At-risk and high-risk medical conditions were ascertained using ICD-9-CM diagnosis codes, ICD-9-CM/HCPCS procedure codes, and HCPCS/NDC drug codes recorded any time before the beginning of the corresponding study year. Operational algorithms that were used to identify at-risk and high-risk conditions are available in [Tables S1 and S2 (online supplement)](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofu024/-/DC1). Persons who were not continuously eligible for comprehensive health (ie, medical and drug) benefits for at least 1 year before January 1st of ≥1 corresponding year were excluded from the study population.

Study Measures {#s2d}
--------------

Episodes of nonbacteremic all-cause pneumonia, nonbacteremic pneumococcal pneumonia, and IPD that occurred from January 1st through December 31st of each study year were identified using operational algorithms based on ICD-9-CM diagnosis codes and HCPCS/NDC drug codes ([Table S3, online supplement](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofu024/-/DC1)). All-cause pneumonia was included as a study measure because *S pneumoniae* infection is the most common cause of bacterial pneumonia, and pathogen-specific diagnostic codes for pneumonia seldom appear in healthcare claims data. Multiple episodes of pneumococcal disease that occurred during a single study year were included as independent events if they were separated by ≥90 days.

Statistical Analyses {#s2e}
--------------------

Rates of pneumococcal disease episodes were estimated within each age group by risk profile as well as individual medical condition, and they were expressed per 100 000 person-years. Rate ratios for disease episodes among persons with at-risk and high-risk conditions, respectively---overall and by individual medical condition---versus their age-matched healthy counterparts were estimated using Poisson regression (SAS version 9.3). Rates of disease and corresponding rate ratios (vs healthy counterparts) were also calculated for at-risk persons by the number of at-risk conditions.

RESULTS {#s3}
=======

Characteristics of the Study Population {#s3a}
---------------------------------------

Persons aged 18--49 years, 50--64 years, and ≥65 years contributed a total of 49.3 million, 30.6 million, and 11.7 million person-years of observation, respectively. Approximately 86% of adults aged 18--49 years had none of the selected chronic or immunocompromising conditions, whereas approximately 12% had ≥1 at-risk condition (and no high-risk conditions), and approximately 2% had a high-risk condition. The prevalence of at-risk and high-risk conditions increased with increasing age: approximately 25% and 6% of adults aged 50 to 64 years, and 39% and 15% of adults aged ≥65 years, had at-risk and high-risk conditions, respectively.

Among adults aged 18--49 years, 10.0% had 1 at-risk condition, 1.2% had 2, and 0.2% had 3 or more; the most common chronic conditions were diabetes (34% of those with ≥1 at-risk condition), asthma (23%), and smoking (20%). In adults 50--64 years of age, 19.6% had 1 at-risk condition, 4.4% had 2, and 1.2% had 3 or more; the most common conditions were diabetes (49%), chronic heart disease (30%), and smoking (13%). In adults ≥65 years of age, 26.4% had 1 at-risk condition, 9.5% had 2, and 3.1% had 3 or more; the most common conditions were chronic heart disease (52%), diabetes (50%), and chronic lung disease (20%). In all 3 age groups, the most common high-risk condition was the presence of diseases associated with immunosuppression or receipt of immunosuppressive drugs.

Rates of Disease {#s3b}
----------------

The rates of all-cause pneumonia (cases per 100 000 person-years) in the study population increased with age and risk profile (Table [1](#OFU024TB1){ref-type="table"}). In healthy adults, the rate increased from 363 in persons aged 18--49 years to 1874 in those aged ≥65 years. Corresponding rates in at-risk adults were 1147 and 5662, and in high-risk adults corresponding rates were 2204 and 7594. Rates of pneumococcal pneumonia and IPD similarly increased with age and risk profile (Table [2](#OFU024TB2){ref-type="table"}). Table 1.Rates of All-Cause Pneumonia Among Healthy, At-Risk, and High-Risk AdultsAll-Cause PneumoniaNo. of Person-YearsAge 18--49 YearsAge 50--64 YearsAge ≥65 YearsAge 18--49 YearsAge 50--64 YearsAge ≥65 YearsRate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Risk Group Healthy42 472 51320 972 9355 389 930363--651--1874-- At-risk5 672 6887 696 2474 579 50511473.2 (3.1--3.2)20243.1 (3.1--3.1)56623.0 (3.0--3.0)  Alcoholism198 416135 21823 90513133.6 (3.5--3.8)32785.0 (4.9--5.2)74003.9 (3.8--4.1)  Asthma1 277 380908 130362 18313893.8 (3.8--3.9)30464.7 (4.6--4.7)85704.6 (4.5--4.6)  Chronic heart disease768 5142 314 4842 363 79817934.9 (4.9--5.0)27794.3 (4.2--4.3)71003.8 (3.8--3.8)  Chronic liver disease117 513175 18450 54020425.6 (5.4--5.9)36465.6 (5.5--5.7)77424.1 (4.0--4.3)  Chronic lung disease406 388844 755882 06131058.6 (8.4--8.7)56188.6 (8.5--8.7)12 3796.6 (6.6--6.7)  Chronic use of oral steroids145 067130 20065 7758732.4 (2.3--2.5)14882.3 (2.2--2.4)36962.0 (1.9--2.1)  Diabetes1 913 6533 807 5052 267 13311343.1 (3.1--3.2)19593.0 (3.0--3.0)52662.8 (2.8--2.8)  Neuromuscular/seizure disorders307 529199 605104 86416774.6 (4.5--4.8)31444.8 (4.7--5.0)85394.6 (4.5--4.7)  Rheumatoid arthritis/Crohn\'s/lupus238 225341 148162 20614914.1 (4.0--4.3)25784.0 (3.9--4.0)64653.5 (3.4--3.5)  Smokers1 118 2961 010 649180 50411883.3 (3.2--3.3)25994.0 (3.9--4.0)66913.6 (3.5--3.6) High-risk1 111 2721 951 1281 774 18122046.1 (6.0--6.2)36015.5 (5.5--5.6)75944.1 (4.0--4.1)  Chronic renal failure122 921233 166344 160403311.1 (10.8--11.4)63759.8 (9.6--10.0)11 8736.3 (6.3--6.4)  Cochlear implant12111306114414043.9 (2.4--6.2)19903.1 (2.1--4.5)45442.4 (1.8--3.2)  Congenital immunodeficiency37 78038 99114 392431211.9 (11.3--12.5)747611.5 (11.1--11.9)14 7387.9 (7.5--8.2)  Diseases of white blood cells55 67994 12346 869509214.0 (14.1--14.6)780612.0 (11.7--12.3)13 2627.1 (6.9--7.3)  Functional/anatomic asplenia53 46455 83442 976661618.2 (17.7--18.9)10 73716.5 (16.1--16.9)15 9768.5 (8.3--8.7)  HIV109 09384 091730620805.7 (5.5--6.0)29474.5 (4.4--4.7)64613.4 (3.2--3.8)  Immunosuppressive drugs/conditions840 8061 654 9701 523 02121886.0 (5.9--0.00)36335.6 (5.5--5.6)72483.9 (3.8--3.9)[^1][^2] Table 2.Rates of Pneumococcal Pneumonia and Invasive Pneumococcal Disease Among Healthy, At-Risk, and High-Risk AdultsPneumococcal PneumoniaInvasive Pneumococcal DiseaseNo. of Person-YearsAge 18--49 YearsAge 50--64 YearsAge ≥65 YearsAge 18--49 YearsAge 50--64 YearsAge ≥65 YearsAge 18--49 YearsAge 50--64 YearsAge ≥65 YearsRate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Rate per 100KRate Ratios\* (95% CI)Risk Group Healthy42 472 51320 972 9355 389 93014--25--67--1.8--4.5--8.3-- At-risk5 672 6887 696 2474 579 505443.1 (3.0--3.3)803.2 (3.0--3.3)2103.1 (3.0--3.2)5.63.0 (2.7--3.5)122.7 (2.5--2.9)232.8 (2.5--3.1)  Alcoholism198 416135 21823 905513.6 (3.0--4.4)1164.6 (3.9--5.4)3054.5 (3.6--5.7)14.17.7 (5.3--11.2)29.66.6 (4.8--9.1)41.85.0 (2.7--9.4)  Asthma1 277 380908 130362 183523.7 (3.4--4.0)1244.9 (4.6--5.2)3985.9 (5.6--6.3)4.52.5 (1.9--3.2)16.73.8 (3.2--4.5)34.24.1 (3.4--5.0)  Chronic heart disease768 5142 314 4842 363 798725.1 (4.6--5.5)1064.2 (4.0--4.4)2543.8 (3.6--3.9)7.23.9 (3.0--5.1)132.9 (2.6--3.3)26.63.2 (2.8--3.6)  Chronic liver disease117 513175 18450 540906.4 (5.3--7.7)1485.8 (5.2--6.6)2874.3 (3.6--5.0)18.710.2 (6.7--15.6)28.56.4 (4.8--8.5)53.46.4 (4.4--9.5)  Chronic lung disease406 388844 755882 0611268.9 (8.1--9.7)2489.8 (9.3--10.3)5167.7 (7.3--8.0)11.66.3 (4.7--8.5)34.47.7 (6.8--8.8)51.16.2 (5.4--7.0)  Chronic use of oral steroids145 067130 20065 775392.7 (2.1--3.5)612.4 (1.9--3.0)1281.9 (1.5--2.4)6.23.4 (1.8--6.5)102.2 (1.3--3.9)15.21.8 (1.0--3.4)  Diabetes1 913 6533 807 5052 267 133443.1 (2.9--3.3)763.0 (2.8--3.1)1872.8 (2.7--2.9)5.53.0 (2.4--3.7)11.62.6 (2.3--2.9)21.12.5 (2.2--2.9)  Neuromuscular/seizure disorders307 529199 605104 864815.7 (5.0--6.5)1365.3 (4.7--6.0)3304.9 (4.4--5.5)7.23.9 (2.5--6.0)21.54.8 (3.6--6.6)38.14.6 (3.3--6.3)  Rheumatoid arthritis/Crohn\'s/lupus238 225341 148162 206634.4 (3.8--5.2)1084.3 (3.8--4.7)2664.0 (3.6--4.4)137.1 (4.9--10.1)21.14.7 (3.7--6.0)33.34.0 (3.0--5.3)  Smokers1 118 2961 010 649180 504423.0 (2.7--3.3)1114.4 (4.1--4.6)2643.9 (3.6--4.3)6.53.6 (2.8--4.5)19.24.3 (3.7--5.0)34.94.2 (3.2--5.5) High-risk1 111 2721 951 1281 774 1811037.3 (6.8--7.7)1495.9 (5.6--6.1)2904.3 (4.1--4.5)18.510.1 (8.7--11.8)30.86.9 (6.2--7.6)36.74.4 (3.9--5.0)  Chronic renal failure122 921233 166344 16019713.9 (12.2--15.8)2854.2 (4.0--4.4)4386.5 (6.1--6.9)26.814.6 (10.3--20.7)57.913.0 (10.8--15.6)506.0 (5.0--7.2)  Cochlear implant12111306114416511.7 (2.9--46.6)0--2623.9 (1.3--12.1)0--0--87.410.5 (1.5--74.8)  Congenital immunodeficiency37 78038 99114 39226518.7 (15.3--22.8)41816.4 (14.1--19.2)6329.4 (7.6--11.6)68.837.5 (25.4--55.4)105.22.2 (1.5--3.4)118.114.2 (8.8--23.1)  Diseases of white blood cells55 67994 12346 86923716.7 (14.1--19.9)33913.3 (11.9--14.9)5658.4 (7.4--9.5)52.128.4 (19.6--41.1)6815.3 (11.8--19.6)110.913.3 (10.0--17.8)  Functional/anatomic asplenia53 46455 83442 97634624.4 (21.1--28.3)46418.3 (16.1--20.7)71010.5 (9.4--11.9)59.932.6 (22.9--46.4)125.428.1 (22.1--35.9)116.314.0 (10.5--18.7)  HIV109 09384 09173061389.8 (8.3--11.5)1656.5 (5.5--7.7)3294.9 (3.3--7.3)40.322.0 (16.2--29.8)54.712.3 (9.1--16.5)27.43.3 (0.8--13.2)  Immunosuppressive drugs/conditions840 8061 654 9701 523 0211007.1 (6.6--7.6)1485.8 (5.5--6.1)2784.1 (4.0--4.3)15.58.4 (7.0--10.1)28.96.5 (5.8--7.2)36.44.4 (3.9--5.0)[^3][^4]

The rates of all-cause pneumonia were consistently higher in at-risk and high-risk persons compared with healthy persons in all age groups. In persons aged 18--49 years, 50--64 years, and ≥65 years with at least 1 at-risk condition, the rate of all-cause pneumonia was 3.2 (95% confidence interval \[CI\], 3.1--3.2), 3.1 (95% CI, 3.1--3.1), and 3.0 (95% CI, 3.0--3.0) times the rate in healthy persons, respectively. In high-risk persons in these age groups, the rate of all-cause pneumonia was 6.1 (95% CI, 6.0--6.2), 5.5 (95% CI, 5.5--5.6), and 4.1 (95% CI, 4.0--4.1) times the rate in healthy persons. Rate ratios for pneumococcal pneumonia and IPD were generally similar (Tables [1](#OFU024TB1){ref-type="table"} and [2](#OFU024TB2){ref-type="table"}).

Notably, the rates of all-cause pneumonia among persons with autoimmune diseases (rheumatoid arthritis, SLE, or Crohn\'s disease) were substantially greater than the rates in healthy persons (Figure [1](#OFU024F1){ref-type="fig"}). Rate ratios in the 3 age groups were 4.1 (95% CI, 4.0--4.3), 4.0 (95% CI, 3.9--4.0), and 3.5 (95% CI, 3.4--3.5), respectively. Corresponding rate ratios for persons with neuromuscular or seizure disorders were 4.6 (4.5--4.8), 4.8 (4.7--5.0), and 4.6 (4.5--4.7). Figure 1.Rates of all-cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease among adults with rheumatoid arthritis, lupus, or Crohn\'s disease versus their healthy counterparts.

Absolute rates of all-cause pneumonia in persons with at-risk conditions substantially increased with the number of concurrent conditions, and they were progressively higher across increasing age groups (Figure [2](#OFU024F2){ref-type="fig"}). Rates in persons with 2 at-risk conditions were generally similar to rates in persons with high-risk conditions, and rates in persons with ≥3 at-risk conditions were substantially higher than rates in persons with high-risk conditions. Because baseline disease rates were lowest among adults aged 18--49 years, the increase in rate ratios with an increasing number of at-risk conditions was most pronounced for this age group: for all-cause pneumonia, rate ratios increased from 2.5 (95% CI, 2.5--2.5) in those with 1 at-risk condition to 6.2 (95% CI, 6.1--6.3) in those with 2 conditions, and 15.6 (95% CI, 15.3--16.0) in those with ≥3 conditions. Results for pneumococcal pneumonia and IPD were similar. Figure 2.Rates of all-cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease among adults with at-risk conditions by number of conditions versus their healthy counterparts

DISCUSSION {#s4}
==========

Our findings, based on 3 large and geographically diverse US populations, indicate that the increased risks of pneumococcal disease associated with established risk factors have persisted in the era of widespread vaccination of children with pneumococcal conjugate vaccines. In our study, 18--49-year-olds with at-risk conditions accounted for 12% of the population but 27% of all-cause pneumonia cases; 50--64-year-olds with at-risk conditions accounted for 25% of the population but 43% of all-cause pneumonia cases; and individuals aged ≥65 years with at-risk conditions accounted for 39% of the population but 52% of all-cause pneumonia cases. Two recent large studies from the United Kingdom and United States found similar persistence of increased risk of IPD in adults with selected medical conditions, although with different relative risks in some instances \[[@OFU024C10], [@OFU024C11]\].

We observed substantially increased rates of pneumococcal disease among persons with \>1 at-risk condition, and disease rates were especially high among those with ≥3 at-risk conditions---for younger adults, an all-cause pneumonia rate 15.6 times that of healthy persons. This phenomenon of "risk stacking"---whereby risk of disease increases with increasing numbers of risk factors---has been noted for other diseases, for example, osteoporotic hip fractures and cardiovascular events \[[@OFU024C12], [@OFU024C13]\]. Although only a small percentage of our study population had \>1 concurrent at-risk condition, especially among the youngest age group, recent evidence from the Centers for Disease Control and Prevention (CDC) has shown that the percentage of older US adults (≥45 years) with 2 or more of 9 selected chronic conditions (most of which are risk factors for pneumococcal disease) increased by 5% in those aged 45--64 and by 7% in those aged ≥65 years between 1999 and 2000 and 2009 and 2010 \[[@OFU024C14]\]. This increase was seen in men and women and across all race and ethnicity groups examined. If this trend continues into the future, risk stacking is likely to account for an increasing proportion of cases of pneumococcal disease.

Two patterns in our results merit explanation. First, rate ratios for the 3 outcomes considered---all-cause pneumonia, pneumococcal pneumonia, and IPD---were similar. This finding is not surprising and is likely explained by 2 factors. The predominant manifestation of IPD is bacteremic pneumonia---70.4% of all cases in the United States in 2009---and the pneumococcus is the most common bacterial pathogen in all-cause pneumonia \[[@OFU024C15]\]. Thus, to a considerable extent, these 3 outcomes represent the same clinical entity of pneumonia caused by pneumococcal infection. Moreover, conditions that predispose to pneumonia caused by pneumococcus are probably not specific to that pathogen. For example, chronic lung disease likely increases the risk of pneumonia caused by a variety of pathogens. The second pattern we observed was that rate ratios were smaller in older persons. This important observation likely reflects a smaller contrast in disease risk between "healthy" older adults and "unhealthy" older adults due to waning immunocompetence that occurs with advancing age.

An additional finding in our study was substantially increased risks of pneumococcal disease associated with 3 relatively common autoimmune diseases (rheumatoid arthritis, SLE, and Crohn\'s disease) and with neuromuscular and seizure disorders. Other investigators have also described increased risks for pneumococcal disease in persons with autoimmune disorders. A large retrospective study from the United Kingdom demonstrated that patients who were admitted to the hospital or received hospital-based care for a variety of immune-mediated diseases, including the 3 of interest in our study, had an elevated risk for IPD \[[@OFU024C7]\]. In another recent large study from the United Kingdom, investigators used a case-control design (17 000 cases) to examine the risk of all-cause pneumonia associated with a variety of conditions that are not well established risk factors for pneumonia \[[@OFU024C8]\]. The adjusted odds ratio for the association between rheumatoid arthritis and IPD was 2.2 (95% CI, 1.7--2.8). We could not determine the extent to which our observed increased rates of disease among persons with rheumatoid arthritis, SLE, and Crohn\'s disease was attributable to the disease itself versus the receipt of immunosuppressive medications used to treat these diseases due to the inability to separate out the effects of treatment versus disease severity---which could be the reason for treatment---using claims data.

We chose to examine the risk of pneumococcal disease associated with neuromuscular and seizure disorders because epilepsy has previously been identified as a risk factor for pneumonia \[[@OFU024C16], [@OFU024C17]\], and because in prior work, in which we studied the risks of pneumococcal disease in children, these disorders were found to be significant risk factors. We initially examined neuromuscular and seizure disorders in our study of children on the basis of a finding that one-third of children who died from influenza in the United States during 2003--2004 had such conditions \[[@OFU024C9]\]. Bhat et al \[[@OFU024C9]\] hypothesized that neuromuscular and seizure disorders may somehow compromise respiratory function in such a way that increases the risk of aspiration, subsequently increasing the risk of influenza complications such as pneumonia.

Our study has several limitations. First, use of operational algorithms and healthcare claims data undoubtedly resulted in misclassification of risk profiles, including both errors of omission and commission. Although it was not possible to formally evaluate the accuracy of these algorithms within the context of this study, we did evaluate the sensitivity of our study results by using alternative approaches to characterizing individual medical conditions and risk profiles, and found our findings largely unchanged. Second, the incidence of pneumococcal pneumonia and IPD in our population is lower than national estimates from the CDC \[[@OFU024C18]\]. However, IPD incidence in our study population followed the same general age distribution as has been reported by the CDC, and imperfect sensitivity of case ascertainment that is proportional across age groups should not impact rate ratios. Third, persons with public or no health insurance are not represented in the study databases, potentially limiting the generalizability of study results to other populations. In addition, our estimates of the percentage of the US population with 1 or more chronic medical conditions will be underestimated to the extent that the under- or uninsured population includes a larger percentage of such persons. Fourth, data used in this analysis did not permit us to identify pneumococcal serotypes causing disease in adults with at-risk or high-risk conditions. It would be of interest to know the proportion of cases among persons in various risk groups due to individual serotypes and according to whether or not they are included in the PCV7, PCV13, PPS23, or no currently available pneumococcal vaccines. Finally, lack of reliable data precluded us from including information on pneumococcal vaccination status in our analyses.

These data support the observation that despite the widespread use of pneumococcal conjugate vaccines in infants and an overall decline in rates of pneumonia and IPD in children and adults, disease rates remain disproportionately high in adults with at-risk and high-risk conditions \[[@OFU024C5], [@OFU024C11], [@OFU024C19], [@OFU024C20]\]. In addition, we have identified a group of adults who are at increased risk for pneumococcal disease due to having medical conditions not currently included within the ACIP recommendations for prevention---including rheumatoid arthritis, SLE, Crohn\'s disease, and neuromuscular and seizure disorders---as well as a small group of adults with ≥3 at-risk conditions whose risk of pneumococcal disease is as high as or higher than those associated with the presence of selected high-risk conditions. In combination with work done by others, our findings suggest that it may be worthwhile to consider expansion of the lists of at-risk and high-risk conditions for which adult pneumococcal vaccination is recommended.

Supplementary Data {#s5}
==================

[Supplementary material](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofu024/-/DC1) is available online at *Open Forum Infectious Diseases* (<http://OpenForumInfectiousDiseases.oxfordjournals.org/>).
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